To study normal skin acute toxicity in Non-Melanoma Skin Cancer (NMSC) patients treated with High Dose Rate (HDR) Plesiotherapy and very high viscosity addition silicone (VHVAS) rubber custom-made molds. VHVAS rubber features excellent mechanical and physical properties which benefit the stability and reproducibility of the implant. On the other hand, the high electron density relative to water of these materials will increase the scatter production, which may be relevant at the mold-skin interface.
Results: DVH analysis showed high dose areas having: D1cc= 8.5 Gy/fr [5.4-14.4 ], D0.5cc= 9.0 Gy/fr [5.4-16 .3], D0.1cc = 10.3 Gy/fr [6.2-22.9 ]. All patients presented radiodermatitis 1 month after treatment (G2: 89%, G3: 11%). 32% presented radiodermatitis at 3 months (G1: 26%, G2: 6%) and only one patient presented radiodermatitis G1 at 6 months. Toxicity score correlation to CTV volume, treatment depth, BED prescribed dose, D1cc, D0.5cc and D0,1cc had no statistical significance (p>0.05). Treated area was found to be predictive of radiodermatitis persistence at 3 months after treatment (p=0.036). Lesions located in the legs showed longer recovery time from radiodermatitis than other locations (4 months vs 1.8 months average).
Conclusion:
The use of these VHVAS moulds was welltolerated by all patients. Our treatments yield similar results to other groups with similar treatment schemes in terms of acute toxicity. We can conclude that VHVAS custom made molds have a good safety profile. (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) only hard-copy CT data, orthogonal x-ray images of the implant and documented 2D dose information were available. The documented 2D dose information consisted of source strength, catheter numbering, catheter loading, and treatment time. The hard-copy CT data was digitized, transferred to DICOM format and imported in Oncentra Brachy (Elekta, v4.3) . The visible OARs were delineated and used catheters were reconstructed. The Ir192-LDR line sources from the original 2D plans were simulated by loading the reconstructed catheters with Ir192-PDR source tracks of the same length as the LDR sources, with a step size of 2.5mm. Simulation of a line source dosimetry was necessary because the planning system did not support LDR planning. All PDR source dwell times were made equal, but scaled to the documented 2D dose distribution to obtain the 3D dose distribution at time of treatment. Scaling was performed at a 2D LDR isodose level below 30% of the prescribed dose in a plane where the documented 2D dose distribution and transformed 3D dose distribution geometrically match. Scaling below 30% is done to avoid effects due to the nonuniform isodose distribution very close to a stepping PDR source. To check the reliability of the method the Total Reference Air Kerma (TRAK) for both 2D LDR and 3D PDR plans were determined and compared. The difference was tested with the Wilcoxon Signed Rank Test for paired variables. To illustrate the applicability of the method the maximum dose, defined as the D0.1cm3, on e.g. chiasm was determined.
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